Yeda Research and Develpment & Co. Ltd

Nanocell Ltd.

Irit Sagi

Tamar Danon

Inna Solomonov

Abraham Shanzer

Rina Arad-Yellin

Eldar Zehorai

Netta Sela

Raghavendra Kikkeri

Ran Afik

Netta Sela-Paswell

Eitan Wong

Raanan Margalit

Ido Amit

Moran Grossman

Dalit Talmi-Frank

Yinon Rudich

Daniel Zajfman

Arnon Henn

Vishnu Mohan

Henrik B Pedersen

Oded Heber

Michael Rappaport

Jacob Halfon

Gabriel Rosenblum

Nir Ben-Chetrit

The present invention relates to a method for increasing the embryo implantation rate in a mammalian uterus, by administering to the uterus of a mammal an effective amount of an extracellular matrix remodeling enzyme, as well as to a product which includes an extracellular remodeling enzyme.

Compositions for remodeling extracellular matrix and methods of use thereof

A method of treating a disease associated with imbalanced or abnormal activity of MMP-7 is diclosed. The method comprises administration of an antibody comprising an antigen recognition region which binds a catalytic site of MMP-7, having complementarity determining region amino acid sequences as set forth in: SEQ ID NOs: 3, 4 and 5 (CDR3), sequentially arranged from N to C on a light chain of the antibody; and SEQ ID NOs: 6, 7 and 8, sequentially arranged from N to C on a heavy chain of the antibody.

Anti-matrix metalloproteinase 7 (MMP-7) inhibitory antibody and uses thereof

The present invention relates to a method for increasing the embryo implantation rate in a mammalian uterus, by administering to the uterus of a mammal an effective amount of an extracellular matrix remodeling enzyme, as well as to a product comprising an extracellular remodeling enzyme.

A method of treating or preventing a disease associated with a secondary infection in a subject infected with a pathogen is provided. The method comprises administering to the subject a therapeutically effective amount of an anti-pathogenic agent directed towards the pathogen and a therapeutically effective amount of an agent which down-regulates at least one extracellular matrix-associated polypeptide.

Methods of preventing secondary infections

A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R, Rand Kwhich renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

Variants of TACE pro-domain as TNF-A inhibitor and their medical use

A method of generating an antibody which inhibits a metalloenzyme is disclosed. The method comprises immunizing a subject with: Antibodies generated by this method are also disclosed as well as uses thereof.

Methods of generating antibodies to metalloenzymes

An article of manufacture is disclosed which comprises at least two active agents, wherein a first of the two active agents comprises an anti-cancer agent or an antifibrotic agent and a second of the at least two active agents downregulates the activity and/or expression of lysyl-oxidase like protein-2 (LOXL-2) and which is capable of altering the structure of the extracellular matrix.

Antibodies targeted against LOXL-2 for the treatment of collagen-associated pathologies

An antibody comprising an antigen recognition region which comprises CDR amino acid sequences set forth in SEQ ID NO: 7, 8, 9, 10, 11 and 12.

Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins

An antibody is disclosed which comprises an antigen recognition region which comprises six CDR amino acid sequences selected from the group consisting of SEQ ID NOs: 4-15. Uses thereof are also disclosed.

Growing community of inventors

Rehovot, Israel

Irit Sagi